Les maladies neurologiques augmentent-elles le risque ?
Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs.
Maladies neurologiquesSensibilitéRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques voltage-dépendants : Questions médicales les plus fréquentes",
"headline": "Bloqueurs de canaux sodiques voltage-dépendants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bloqueurs de canaux sodiques voltage-dépendants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques",
"url": "https://questionsmedicales.fr/mesh/D026941",
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques",
"code": {
"@type": "MedicalCode",
"code": "D026941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.720"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"alternateName": "Voltage-Gated Sodium Channel Blockers",
"code": {
"@type": "MedicalCode",
"code": "D061567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "William A Catterall",
"url": "https://questionsmedicales.fr/author/William%20A%20Catterall",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA 98195, USA. Electronic address: wcatt@uw.edu."
}
},
{
"@type": "Person",
"name": "Piyasuda Pukkanasut",
"url": "https://questionsmedicales.fr/author/Piyasuda%20Pukkanasut",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Sadanandan E Velu",
"url": "https://questionsmedicales.fr/author/Sadanandan%20E%20Velu",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Tamer M Gamal El-Din",
"url": "https://questionsmedicales.fr/author/Tamer%20M%20Gamal%20El-Din",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA, United States."
}
},
{
"@type": "Person",
"name": "Christopher L-H Huang",
"url": "https://questionsmedicales.fr/author/Christopher%20L-H%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Hopkins Building, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pleiotropic effects of clopidogrel.",
"datePublished": "2022-06-09",
"url": "https://questionsmedicales.fr/article/35678974",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11302-022-09876-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ticagrelor Aspirin vs Clopidogrel Aspirin in",
"datePublished": "2022-12-19",
"url": "https://questionsmedicales.fr/article/36535779",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/WNL.0000000000201454"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36315949",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7326/M22-1667"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential inhibition of platelet function by cilostazol in combination with clopidogrel.",
"datePublished": "2023-09-23",
"url": "https://questionsmedicales.fr/article/37740121",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00228-023-03553-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel.",
"datePublished": "2022-12-02",
"url": "https://questionsmedicales.fr/article/36463859",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000527816"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002317"
},
{
"@type": "ListItem",
"position": 6,
"name": "Bloqueurs de canaux sodiques",
"item": "https://questionsmedicales.fr/mesh/D026941"
},
{
"@type": "ListItem",
"position": 7,
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"item": "https://questionsmedicales.fr/mesh/D061567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bloqueurs de canaux sodiques voltage-dépendants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?\nQuels tests sont utilisés pour évaluer l'effet des bloqueurs ?\nQuels symptômes indiquent une surdose de bloqueurs ?\nComment différencier les types de bloqueurs de canaux ?\nQuels antécédents médicaux sont pertinents pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Clopidogrel#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les symptômes d'une intoxication aiguë ?\nComment se manifestent les effets secondaires des bloqueurs ?\nQuels signes indiquent une réaction allergique ?\nLes bloqueurs affectent-ils la respiration ?\nQuels symptômes neurologiques peuvent apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Clopidogrel#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment prévenir les effets indésirables des bloqueurs ?\nQuelles précautions doivent être prises avant la prescription ?\nLes patients doivent-ils être informés des risques ?\nComment éviter les interactions médicamenteuses ?\nQuelles sont les recommandations pour les patients à risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Clopidogrel#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quel est le traitement d'une surdose de bloqueurs ?\nComment gérer les effets secondaires des bloqueurs ?\nQuels médicaments peuvent interagir avec les bloqueurs ?\nLes bloqueurs sont-ils utilisés en anesthésie ?\nQuelle est l'importance de la surveillance pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Clopidogrel#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quelles complications peuvent survenir avec les bloqueurs ?\nComment les complications sont-elles gérées ?\nLes complications sont-elles fréquentes ?\nQuels facteurs augmentent le risque de complications ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Clopidogrel#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les principaux facteurs de risque ?\nComment l'âge influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'usage de drogues illicites est-il un facteur de risque ?\nLes maladies neurologiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Clopidogrel#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'historique médical, les symptômes cliniques et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'effet des bloqueurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des électrocardiogrammes et des tests de conduction nerveuse peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de bloqueurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, une arythmie cardiaque et une dépression respiratoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment différencier les types de bloqueurs de canaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse des effets cliniques et des mécanismes d'action aide à les différencier."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont pertinents pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques ou neurologiques sont cruciaux pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une intoxication aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des nausées, des troubles de la vision et des convulsions."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les effets secondaires des bloqueurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des étourdissements, des maux de tête et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons et un gonflement peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les bloqueurs affectent-ils la respiration ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner une dépression respiratoire dans les cas graves."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques peuvent apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, des troubles de la conscience et des paralysies peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des bloqueurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prescription appropriée et une éducation du patient sont essentielles pour prévenir les effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles précautions doivent être prises avant la prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicaux et les allergies du patient est crucial avant la prescription."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients des risques et des signes d'intoxication est essentiel."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen minutieux des médicaments prescrits et des antécédents est nécessaire pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les patients à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients à risque doivent être suivis de près et éduqués sur les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quel est le traitement d'une surdose de bloqueurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des soins de soutien, l'administration de charbon actif et des antidotes si disponibles."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des bloqueurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique l'ajustement de la dose ou le changement de médicament selon les symptômes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interagir avec les bloqueurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les antidépresseurs et les anesthésiques peuvent interagir."
}
},
{
"@type": "Question",
"name": "Les bloqueurs sont-ils utilisés en anesthésie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains bloqueurs de canaux sodiques sont utilisés pour induire une anesthésie locale."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance pendant le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter les effets indésirables et ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les bloqueurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des arythmies, des convulsions et des défaillances respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une intervention rapide et un traitement symptomatique."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, surtout en cas de surdose ou d'interactions."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge avancé, les maladies cardiaques et l'utilisation concomitante d'autres médicaments augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance attentive et une éducation adéquate peuvent aider à prévenir certaines complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, l'âge et l'utilisation d'autres médicaments sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées ont un risque accru de complications en raison de la polypharmacie et de la fragilité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques ou neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'usage de drogues illicites est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage de certaines drogues peut interagir avec les bloqueurs et augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les maladies neurologiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs."
}
}
]
}
]
}
Genotype data of the Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) trial showed that efficacy of clopidogrel aspirin depended on...
Data were obtained from Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. Low-risk and high-risk profiles were defined by...
A total of 6,412...
This post hoc analysis of CHANCE-2 trial showed that...
This study provides Class II evidence that...
URL: www....
gov. Unique identifier: NCT04078737....
Evidence on the risk-benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent....
To investigate the effect of renal function on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin treatment....
Post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT04078737)....
202 centers in China....
Ticagrelor-aspirin and clopidogrel-aspirin....
Renal function was evaluated by estimated glomerular filtration rate (eGFR) levels. The primary efficacy and safety outcomes were recurrent stroke and severe or moderate bleeding within 90 days, respe...
Among 6378 patients, 4050 (63.5%) had normal (eGFR ≥90 mL/min/1.73 m...
Renal function was only evaluated by using eGFR, and the proportion of patients with severely decreased renal function was low....
Patients with normal, rather than impaired, renal function received greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin....
Ministry of Science and Technology of the People's Republic of China....
To assess the antiplatelet effect of cilostazol clinically, we compared the effects of cilostazol in combination with clopidogrel on various platelet function tests....
We recruited patients with ischemic stroke at high risk of recurrence who were treated with clopidogrel alone within 180 days after stroke onset. Subjects underwent baseline platelet function tests, a...
Thirty-four patients were enrolled, but 4 patients were excluded for various reasons. In total, 30 subjects (13 in DAPT and 17 in SAPT group) were analyzed. Adenosine diphosphate- and collagen-induced...
The inhibitory effects of adjunctive cilostazol added to clopidogrel on platelet function differed by type of platelet function test. VerifyNow % inhibition and PRI were more inhibited than the other ...
CSPS.com substudy in TWMU (UMIN000026672), registered on April 1, 2017. This study was performed as a substudy of CSPS.com (UMIN000012180, registered on October 31, 2013) and was retrospectively regis...
Antithrombotic regimen in patients on oral anticoagulation (OAC) post-percutaneous coronary intervention (PCI) is challenging. At least, one antiplatelet agent in combination with OAC is recommended a...
In this retrospective single-center database analysis, we investigated platelet reactivity by light transmission aggregometry in patients under different antiplatelet regimes. Results were presented a...
755 patients were enrolled. 677 were on ASA, 521 were on clopidogrel, and 198 had OAC. Overall mean age was 73 ± 13.4 years, and 458 (60.7%) were male. HTPR to ASA occurred in 94/677 patients (13.9%),...
Impaired pharmacodynamic response to clopidogrel was more frequent as HTPR to ASA. Hence, ASA should be tested in combination with OAC post-PCI....
Clopidogrel is effective at decreasing cardiovascular events in patients with peripheral artery disease (PAD); however, its effect on limb outcomes are less known. This study investigated the variabil...
Three hundred subjects were enrolled in the Platelet Activity and Cardiovascular Events (PACE) study prior to lower extremity revascularization, of whom 104 were on clopidogrel. Light transmission pla...
Overall, the median age was 70 (63, 76) and 35.6% were female. Twenty-nine (27.9%) patients experienced MALE during their follow-up. Median aggregation to ADP 2...
Among patients undergoing lower extremity revascularization on clopidogrel, higher baseline percent aggregation is associated with increased risk for major adverse limb events....
Clopidogrel is a widely prescribed prodrug with antithrombotic activity that functions by irreversibly inhibiting the P2Y12 receptors on platelets; nevertheless, drug-induced eosinophilia from this dr...
Both clopidogrel and atorvastatin metabolism are rooted in hepatic cytochrome p450 activation. There are published reports of atorvastatin interfering with clopidogrel metabolism by inhibiting the act...
All patients undergoing revascularization between December 2020 and August 2022 were prospectively evaluated. Patients on clopidogrel and atorvastatin were compared to those on clopidogrel alone. Seri...
Over the study period, a total of 182 patients were enrolled. Of this cohort 72 patients met study criteria. 87 samples from the 72 patients were analyzed. 31 (43.05%) patients were on clopidogrel alo...
Patients on clopidogrel and atorvastatin showed significantly less platelet inhibition compared to those on clopidogrel alone, supporting the concept that atorvastatin may interfere with the therapeut...
This study aims to compare the effects of ticagrelor and clopidogrel on platelet function, cardiovascular prognosis, and bleeding in patients with unstable angina pectoris....
Patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI) were enrolled (January 2018-December 2019). In total, 212 patients were treated with ticagrelor (90 mg twice ...
The PAR was significantly slower with ticagrelor (P < 0.001). hs-TnT, NT-proBNP, CRP, and h-FABP increased after compared with before PCI in both groups (P < 0.05). hs-TnT (P < 0.001) and h-FABP (P < ...
Ticagrelor was more effective in suppressing the PAR than clopidogrel and reduced PCI-induced myocardial injury in patients with unstable angina pectoris. However, it increased in-hospital and 12-mont...
Clopidogrel resistance (CR) is mostly caused by interindividual variability of the platelet inhibition of clopidogrel, which may induce cardiovascular events. The aim of this research was to evaluate ...
72 patients(36 CR and 36 non-CR) who underwent ACS were included in this study. The VerifyNow P2Y12 assay was selected to evaluate residual platelet reactivity, and bisulfite pyrosequencing methods wa...
Subunit analysis indicated that for patients whose HbA1c levels were ≥6.5% or whose GLU levels were ≥7 mmol/L, lower methylation of cg01534253 indicated a poorer clopidogrel response. In addition, CRE...
Our findings were likely to provide fresh understanding for the new mechanism of platelet inhibition failure and promote individualized antiplatelet therapy....